1709P Outcomes with novel combinations in non-clear cell renal cell carcinoma (nccRCC): ORACLE study

D. Kilari; A. Szabo; M.A. Bilen; Y. Ged; B.L. Maughan; C. Hwang; H. McManus; P.M. Coelho Barata; A. Desai; Y. Zakharia; H. Emamekhoo; A. Tripathi; T. Rose; P. Ghatalia; M.A. Reimers; E. Heath; J.M. King; B.I. Rini; J. Brugarolas; R.R. McKay

doi:10.1016/j.annonc.2024.08.1802

Back

1709P Outcomes with novel combinations in non-clear cell renal cell carcinoma (nccRCC): ORACLE study

Abstract

Peer reviewed

1709P Outcomes with novel combinations in non-clear cell renal cell carcinoma (nccRCC): ORACLE study

D. Kilari, A. Szabo, M.A. Bilen, Y. Ged, B.L. Maughan, C. Hwang, H. McManus, P.M. Coelho Barata, A. Desai, Y. Zakharia, …

Annals of oncology, Vol.35(Supplement 2), pp.S1024-S1025

09/2024

DOI: 10.1016/j.annonc.2024.08.1802

View Online

Abstract

Background There is a paucity of data to guide management of nccRCC due to the heterogeneity and rarity of these tumors. Limited data exists regarding the clinical activity of combination therapies in subtypes of advanced nccRCC. Methods In this multicenter retrospective analysis, we evaluated the efficacy of combination systemic therapy from 2012-2024. in patients(pts) with nccRCC. Eligible pts included those with nccRCC and receipt of any combination regimens including IO-IO, IO-VEGF, mTOR-VEGF during any line of treatment. The primary endpoint was objective response rate (ORR) assessed by investigator review. Secondary endpoints were progression- free survival (PFS), disease control rate (DCR), and overall survival (OS). Results 253 pts received combination regimens. The median age was 59 years; 72% were male and 64% white. Histologies included papillary (38%), unclassified (34%), chromophobe (16%), translocation (8%), and other (4%). 23% had sarcomatoid and/or rhabdoid differentiation. 73% had prior nephrectomy, 82% were IMDC intermediate/poor risk. 23% and 28% had liver and bone metastasis respectively. The majority (69%) received combination treatment as first line. Comparison of outcomes based on treatment regimen and subtype is shown in the table. ORR/DCR/PFS was significantly lower when combination regimens were utilized in second or later line compared to front line setting. Conclusions Limited antitumor activity was observed with novel combinations in nccRCC in both frontline and later line setting. nccRCC subsets appear to respond differentially based on the type of combination regimen. Optimal management of nccRCC remains an unmet need.

Details

Title: Subtitle: 1709P Outcomes with novel combinations in non-clear cell renal cell carcinoma (nccRCC): ORACLE study
Creators: D. Kilari - Medical College of Wisconsin
A. Szabo - Medical College of Wisconsin
M.A. Bilen - Winship Cancer Institute
Y. Ged - Johns Hopkins Hospital
B.L. Maughan - University of Utah
C. Hwang - Henry Ford Health System
H. McManus - Duke University
P.M. Coelho Barata - University Hospitals Seidman Cancer Center
A. Desai - University of California, San Francisco
Y. Zakharia - University of Iowa
H. Emamekhoo - University of Wisconsin Carbone Cancer Center
A. Tripathi - City Of Hope National Medical Center
T. Rose - UNC Lineberger Comprehensive Cancer Center
P. Ghatalia - Fox Chase Cancer Center
M.A. Reimers - Washington University in St. Louis School of Medicine
E. Heath - The Barbara Ann Karmanos Cancer Institute
J.M. King - Indiana University
B.I. Rini - Vanderbilt-Ingram Cancer Center
J. Brugarolas - The University of Texas Southwestern Medical Center
R.R. McKay - University of California, San Diego
Resource Type: Abstract
Publication Details: Annals of oncology, Vol.35(Supplement 2), pp.S1024-S1025
Publisher: Elsevier Ltd
DOI: 10.1016/j.annonc.2024.08.1802
ISSN: 0923-7534
Language: English
Date published: 09/2024
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
Record Identifier: 9984708762602771

Metrics

1 Record Views